Peter Greenleaf

Peter Greenleaf

Chief Executive Officer at AURINIA PHARMACEUTICALS INC.

Net worth: 8 M $ as of 2024-03-30

54 year
Health Technology
Commercial Services
Finance

Profile

Peter S.
Greenleaf
currently works at Aurinia Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2019, Maryland Venture Fund, as Chairman, Revolo Biotherapeutics Ltd., as Chairman from 2020, Pharmaceutical Research & Manufacturers of America, as Director, ValenzaBio, Inc., as Director, and Petrichor Healthcare Capital Management LP, as Advisory.
Mr. Greenleaf also formerly worked at Histogenics Corp., as President, Chief Executive Officer & Director from 2013 to 2014, Sucampo Pharmaceuticals LLC, as Chairman & Chief Executive Officer from 2016 to 2018, BioDelivery Sciences International, Inc., as Chairman from 2018 to 2022, Antares Pharma, Inc., as Independent Director from 2018 to 2022, Mast Therapeutics, Inc., as Independent Director, Oldtech, Inc., as Director, Kiora Pharmaceuticals, Inc., as Director from 2018 to 2020, Biotechnology Innovation Organization, as Director, Melinta Subsidiary Corp., as Director, Tech Council of Maryland, Inc., as Director, LigoCyte Pharmaceuticals, Inc., as Director, Mirna Therapeutics, Inc., as Independent Director, Corridor Pharmaceuticals, Inc., as Director, Avalo Therapeutics, Inc., as Director from 2019 to 2020, Savara, Inc., as Director, OS Therapies, Inc., as Director, Centocor, Inc., as VP-US Gastroenterology Commercial Group, MedImmune LLC, as President from 2006 to 2013, US Healthcare, Inc., as Principal, Hallmark Cards, Inc., as Principal, MedImmune Ventures, Inc., as President from 2010 to 2013, Roche Diagnostics Corp., as Principal from 1996 to 1998, and The University of Maryland Baltimore Foundation, Inc., as Trustee.
Mr. Greenleaf received his Masters Business Admin degree from St. Joseph's University and undergraduate degree from Western Connecticut State University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-03-05 1,522,114 ( 1.05% ) 8 M $ 2024-03-30

Peter Greenleaf active positions

CompaniesPositionStart
AURINIA PHARMACEUTICALS INC. Chief Executive Officer 2019-04-28
Consultant / Advisor -
Chairman 2020-12-16
Director/Board Member -
Chairman -
Director/Board Member -
All active positions of Peter Greenleaf

Former positions of Peter Greenleaf

CompaniesPositionEnd
ANTARES PHARMA, INC. Director/Board Member 2022-05-23
BIODELIVERY SCIENCES INTERNATIONAL, INC. Chairman 2022-03-21
AVALO THERAPEUTICS, INC. Chief Executive Officer 2019-04-14
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
See the detail of Peter Greenleaf's experience

Training of Peter Greenleaf

St. Joseph's University Masters Business Admin
Western Connecticut State University Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter Greenleaf's experience

Connections

99

1st degree connections

31

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies4
KIORA PHARMACEUTICALS, INC.

Health Technology

AVALO THERAPEUTICS, INC.

Health Technology

AURINIA PHARMACEUTICALS INC.

Health Technology

SAVARA INC.

Health Technology

Private companies25

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

LigoCyte Pharmaceuticals, Inc.

Health Technology

The University of Maryland Baltimore Foundation, Inc.

Miscellaneous

Finance

Health Technology

Health Technology

Finance

Commercial Services

Health Technology

Commercial Services

See company connections
  1. Stock Market
  2. Insiders
  3. Peter Greenleaf